# 18F-FSPG PET/CT for Cancer Patients on Therapy

> **NCT02599194** · PHASE2 · COMPLETED · sponsor: **Andrei Iagaru** · enrollment: 7 (actual)

## Conditions studied

- B-Cell Neoplasm
- Estrogen Receptor Negative
- HER2/Neu Negative
- Metastatic Renal Cell Cancer
- Progesterone Receptor Negative
- Stage III Mesothelioma
- Stage III Renal Cell Cancer
- Stage IIIA Breast Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Mesothelioma
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Renal Cell Cancer
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** 18F-FSPG
- **DRUG:** 18F-FDG

## Key facts

- **NCT ID:** NCT02599194
- **Lead sponsor:** Andrei Iagaru
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-12-14
- **Final completion:** 2016-12-14
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599194, "18F-FSPG PET/CT for Cancer Patients on Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02599194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*